Synthesis and in vitro antibacterial activity of fluoroquinolone derivatives containing 3-(N′-alkoxycarbamimidoyl)-4-(alkoxyimino) pyrrolidines

European Journal of Medicinal Chemistry

Volumn 45, Issue 11, 2010, Pages 5498-5506

  Guo, Qiang ^a   Feng, Lian Shun ^a   Liu, Ming Liang ^a   Zhang, Yi Bin ^a   Chai, Yun ^a   Lv, Kai ^a   Guo, Hui Yuan ^a   Han, Li You ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

Author keywords

Antibacterial activity; Fluoroquinolones; Synthesis

Indexed keywords

3 (N' ALKOXYCARBAMIMIDOYL) 4 (ALKOXYIMINO) PYRROLIDINE; 3 (N' ALKOXYCARBAMIMIDOYL) 4(ALKOXYIMINO)PYRROLIDINE; 7 [3 (N' ALKOXYCARBAMIMIDOYL) 4 (ALKOXYIMINO)PYRROLIDIN 1 YL]; ANTIINFECTIVE AGENT; GEMIFLOXACIN; LEVOFLOXACIN; N TERT BUTOXYCARBONYL 2 (2 CYANOETHYL)AMINOACETIC ACID ETHYL ESTER; N TERT BUTOXYCARBONYL 3 (N' ALKOXYCARBAMIMIDOYL) 4 (ALKOXYIMINO)PYRROLIDINE; N TERT BUTOXYCARBONYL 3 CYAN 4 OXOPYRROLIDINE; N TERT BUTOXYCARBONYL 3 CYANO 4(ALKYLOXYIMINO)PYRROLIDINE; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENTEROCOCCUS FAECIUM; HETERONUCLEAR NUCLEAR MAGNETIC RESONANCE; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MASS SPECTROMETRY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS;

ANTI-BACTERIAL AGENTS; CRYSTALLOGRAPHY, X-RAY; FLUOROQUINOLONES; MAGNETIC RESONANCE SPECTROSCOPY; PYRROLIDINES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 77957825219     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2010.08.050     Document Type: Article

References (16)

1. K. Drlica, M. Malik, R.J. Kerns, and X.L. Zhao Antimicrob. Agents Chemother. 52 2008 385 392
2. D.J. Dwyer, M.A. Kohanski, B. Hayete, and J.J. Collins Mol. Syst. Biol. 3 2007 142 156
3. D.R. Choi, J.H. Shin, J. Yang, S.Y. Yoon, and Y.H. Yung Bioorg. Med. Chem. Lett. 14 2004 1273 1277
4. C.Y. Hong, Y.K. Kim, Y.H. Lee, and J.H. Kwak Bioorg. Med. Chem. Lett. 8 1998 221 226
5. V. Cecchetti, A. Fravolini, M.C. Lorenzini, O. Tabarrini, P. Terni, and T. Xin J. Med. Chem. 39 1996 436 445
6. L.J.V. Piddock Antimicrob. Agents Chemother. 38 1994 163 169
7. A. Bryskier, and J.F. Chantot Drugs 49 Suppl. 2 1995 16 28
8. H. Koga, A. Itoh, S. Murayama, S. Suzue, and T. Irikura J. Med. Chem. 23 1980 1358 1363
9. J.M. Domagala J. Antimicrob. Chemother. 33 1994 685 706
10. C.Y. Hong, Y.K. Kim, J.H. Chang, S.H. Kim, H. Choi, D.H. Nam, Y.Z. Kim, and J.H. Kwak J. Med. Chem. 40 1997 3584 3593
11. Z.L. Wan, Y. Chai, M.L. Liu, and H.Y. Guo Chin. J. Med. Chem. 19 2009 109 111
12. J.X. Wang, Q. Guo, Y. Chai, L.S. Feng, H.Y. Guo, and M.L. Liu Chin. Chem. Lett. 21 2010 55 58
13. Y.B. Zhang, L.S. Feng, X.F. You, Q. Guo, H.Y. Guo, and M.L. Liu Arch. Pharm. Chem. Life Sci. 343 2010 143 151
14. Y. Chai, Z.L. Wan, B. Wang, H.Y. Guo, and M.L. Liu Eur. J. Med. Chem. 44 2009 4063 4069
15. Q. Guo, L.Y. Sun, H.Y. Guo, and M.L. Liu Acta Crystallogr. E. E65 2009 o580
16. MICs were determined as described by the NCCLS see: National Committee for Clinical Laboratory Standards, Performance Standards for Antimicrobial Susceptibility Testing: 11th Informational Supplement vol. 21 2001 National Committee for Clinical Laboratory Standards Wayne, PA M100-S11. The MIC was defined as the lowest concentration of each compound resulting in inhibition of visible growth of bacteria after incubation at 35°C for 18-24 h